Myriad GeneticsSTU:MYD -1.68%53 Market Cap is €473.6 Mil as of Jul. 01, 2026. GuruFocus rates STU:MYD with a GF Score™ of 53/100 and a GF Value™ of €13.15 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 218 Medical Diagnostics & Research companies, Myriad Genetics ranks better than 70.64% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Myriad Genetics's share price for the quarter that ended in Mar. 2026 was €3.86. Myriad Genetics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 94.4 Mil. Therefore, Myriad Genetics's market cap for the quarter that ended in Mar. 2026 was €364.4 Mil.
Myriad Genetics's quarterly market cap
declined
from Sep. 2025 (€567.6 Mil) to Dec. 2025 (€495.6 Mil) and
declined
from Dec. 2025 (€495.6 Mil) to Mar. 2026 (€364.4 Mil).
Myriad Genetics's annual market cap
declined
from Dec. 2023 (€1,591.2 Mil) to Dec. 2024 (€1,159.5 Mil) and
declined
from Dec. 2024 (€1,159.5 Mil) to Dec. 2025 (€495.6 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Myriad Genetics's Enterprise Value for Today is €550.1 Mil.
Myriad Genetics (STU:MYD) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Myriad Genetics Market Cap Related Terms
Myriad Genetics Market Cap Historical Data
* Premium members only.
The historical data trend for Myriad Genetics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:MYD vs FLGT, CSTL, BDSX: Market Cap Comparison
For the Diagnostics & Research subindustry, Myriad Genetics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Market Cap distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Myriad Genetics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics (STU:MYD) has a Market Cap of €473.6 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Myriad Genetics and its competitors. According to the industry distribution chart, Myriad Genetics ranks #64 out of 218 companies in the Medical Diagnostics & Research industry, placing it in the top 29.4%.
Is Myriad Genetics' Market Cap too high?
Myriad Genetics' current Market Cap is €473.6 Mil. Based on the distribution chart, Myriad Genetics ranks #64 out of 218 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Myriad Genetics has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Market Cap compare to FLGT and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Myriad Genetics ranks #64 out of 218 companies for Market Cap. This puts Myriad Genetics in the upper half of its industry. The industry median Market Cap is 58.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 58.23, based on 218 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Myriad Genetics and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 58.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myriad Genetics's current Market Cap is €473.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €13.15, compared to a current price of €4.96 — trading 62.3% below its estimated fair value. The current Market Cap is €473.6 Mil. Myriad Genetics' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current Market Cap is €473.6 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myriad Genetics (STU:MYD) Overvalued in 2026?
Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued.
The current stock price of €4.96 is trading 62.3% below its estimated GF Value™ of €13.15.
GuruFocus considers Myriad Genetics to be Possible Value Trap.
Key valuation signals for STU:MYD:
Market Cap: €473.6 Mil
GF Value™: €13.15 vs. price of €4.96 (62.3% below fair value)
No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
53GF Score
Get the complete analysis for STU:MYD
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MYD has been successfully added to your 
